Unicycive Therapeutics, Inc.
NASDAQ:UNCY · NASDAQ Capital Market
-$0.44 today
Vol 1.11M · Avg 0.63M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.9%
avg 560.2%
ROIC
-97.1%
avg 415.9%
ROA
-54.0%
avg -2287.2%
Analysis
ROA is currently the strongest return metric at -54.0% versus its period average of -2287.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Shalabh K. Gupta | Founder, Chairman, Chief Executive Officer & President | $1.06M | — | 52 | $169,500.00 | 0.79% |
Pramod Gupta | Executive Vice President of Pharmaceutical and Business Operations | $666,900.00 | — | 66 | $169,500.00 | 0.79% |
Douglas Jermasek | Executive Vice President of Corporate Strategy | $440,138.00 | — | 65 | $169,500.00 | 0.79% |
John W. Townsend | Chief Financial Officer | $197,864.00 | — | 64 | $169,500.00 | 0.79% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +121.2% (8yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +121.2% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
MindWalk Holdings Corp.
NASDAQ:HYFT
$72.87M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Who manages UNCY?
Unicycive Therapeutics, Inc. (UNCY) lists 4 active executives. The top listed executive is Pramod Gupta, Executive Vice President of Pharmaceutical and Business Operations.
Are UNCY insiders buying or selling?
Recent insider activity shows net buying of $5.54B.
Explore More
Continue the stock analysis
Jump to another research area for this company.